Troy Wichterman Sells 1,033 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 1,033 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $25.13, for a total value of $25,959.29. Following the transaction, the chief financial officer owned 151,736 shares of the company’s stock, valued at approximately $3,813,125.68. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Thursday, December 4th, Troy Wichterman sold 30,000 shares of BioLife Solutions stock. The stock was sold at an average price of $25.72, for a total transaction of $771,600.00.
• On Tuesday, November 25th, Troy Wichterman sold 584 shares of BioLife Solutions stock. The shares were sold at an average price of $26.74, for a total transaction of $15,616.16.
• On Thursday, October 9th, Troy Wichterman sold 833 shares of BioLife Solutions stock. The shares were sold at an average price of $27.36, for a total transaction of $22,790.88.

BioLife Solutions Trading Up 1.6%

BLFS stock traded up $0.40 during mid-day trading on Wednesday, hitting $25.01. 296,709 shares of the company were exchanged, compared to its average volume of 445,500. The firm has a fifty day simple moving average of $26.39 and a 200 day simple moving average of $24.51. The company has a market capitalization of $1.20 billion, a PE ratio of -357.23 and a beta of 1.93. BioLife Solutions, Inc. has a twelve month low of $19.10 and a twelve month high of $29.62.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors have recently made changes to their positions in BLFS. Invesco Ltd. raised its position in shares of BioLife Solutions by 0.5% during the 3rd quarter. Invesco Ltd. now owns 3,599,444 shares of the medical equipment provider’s stock worth $91,822,000 after purchasing an additional 18,666 shares during the period. Vanguard Group Inc. grew its stake in BioLife Solutions by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,967,518 shares of the medical equipment provider’s stock worth $75,701,000 after buying an additional 70,248 shares during the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in BioLife Solutions in the first quarter worth $30,789,000. Ameriprise Financial Inc. lifted its stake in BioLife Solutions by 11.3% in the second quarter. Ameriprise Financial Inc. now owns 1,080,371 shares of the medical equipment provider’s stock valued at $23,271,000 after buying an additional 109,959 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of BioLife Solutions by 2.1% during the third quarter. Dimensional Fund Advisors LP now owns 1,003,383 shares of the medical equipment provider’s stock valued at $25,592,000 after acquiring an additional 20,175 shares during the period. 93.24% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on BLFS shares. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of BioLife Solutions in a report on Monday, November 24th. Wall Street Zen lowered BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Sunday, November 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. Finally, Zacks Research cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.75.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.